As agents targeting the Ang/Tie-signaling pathway, alone or in combination with VEGF inhibition, are currently in phase I and phase II trials (www.clinicaltrials.gov), we aimed to evaluate the prognostic relevance of all angiopoietins, and their receptor Tie-2 in both tumor and stromal cells in a large unselected cohort of NSCLC patients. This evidence concerns the gene TEK and neoplasm.